Breaking Finance News

Robert W. Baird issued a report on QuintilesIMS (US:Q), upping its target to $93.00 earlier today

Only yesterday QuintilesIMS (US:Q) traded 1.53% higher at $87.86. Q’s 50-day average is $90.01 and its two hundred day average is $83.51. With the last stock price up 6.47% relative to the two hundred day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 1,006,508 shares of Q traded hands, up from an average volume of 992,995

Robert W. Baird increased the stock price target of QuintilesIMS (US:Q) to $93.00 reporting a potential upside of 0.06%.

Previously on Thursday May 04, 2017, Mizuho Securities reported on QuintilesIMS (US:Q) increased the target price from $90.00 to $93.00. At the time, this indicated a possible upside of 0.13%.

Performance Chart

QuintilesIMS (US:Q)

With a total market value of $0, QuintilesIMS has 52 week low of $70.10 and a 52 week high of $93.53 with a P/E ratio of 257.71 .

In addition to Robert W. Baird reporting its stock price target, a total of 15 brokerages have issued a ratings update on the company. The average stock price target is $76.50 with eight brokerages rating the company a strong buy, 9 brokers rating the stock a buy, 2 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and lastly zero firms rating the stock a sell.

About QuintilesIMS (US:Q)

Quintiles IMS Holdings, Inc., formerly Quintiles Transnational Holdings Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.